Chronic Otitis Externa (Investigational Adjunct)
Investigational adjunct for refractory chronic otitis externa; topical antimicrobials, aural toilet, and predisposing-factor management remain evidence-based.
Краткая информация для пациента
- Есть ли FDA-допуск для этого показания?
- Not FDA-cleared for chronic otitis externa. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- Какие доказательства существуют?
- Tier C (investigational). No controlled trials. Evidence-based first-line management is otologic examination to identify the cause (eczematous, fungal, bacterial, foreign body, underlying cholesteatoma), aural toilet, topical corticosteroid drops for inflammatory disease, topical antifungal for otomycosis, topical antibiotic-steroid combinations for bacterial disease, and identification and avoidance of triggers (water exposure, cotton swab use, hearing aids).
- Основные риски
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Periauricular placement near the ear canal carries bleeding and infection risks in already inflamed tissue
- Aeromonas may add a second pathogen to an already infected ear
- Bites cannot be placed inside the ear canal — that is unsafe
- Кому не следует это рассматривать
- Patients without ENT evaluation to confirm the diagnosis and rule out malignant otitis externa, cholesteatoma, or tumor
- Patients with active fungal or bacterial infection (need targeted topical therapy)
- Diabetic or immunocompromised patients with otitis externa (high risk of skull-base osteomyelitis)
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
- People with hemophilia or any other inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL)
- People with an active infection at the planned application site
- О чём спросить врача
- Has ENT evaluated my ear canal and ruled out malignant otitis externa or other serious causes?
- Have appropriate topical antibiotic, antifungal, or steroid drops been tried?
- Have aural toileting and trigger avoidance been addressed?
- What is the published evidence base for leeches in otitis externa?
- Where exactly will leeches be placed, and how is proximity to the ear canal managed?
- How will worsening infection be detected during the course?
- Когда срочно обратиться за медицинской помощью
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Severe ear pain disproportionate to physical findings (possible malignant otitis externa, especially in diabetics)
- Facial weakness, severe headache, or fever (could indicate skull-base osteomyelitis)
- New hearing loss, vertigo, or persistent discharge
Что это НЕ означает
- It does not mean leech therapy is FDA-cleared for otitis externa — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace targeted antibiotic, antifungal, or steroid topical therapy.
- It does not exclude malignant otitis externa, cholesteatoma, or ear canal tumor.
- It does not address triggers (water, cotton swabs, hearing aids).
- It does not have controlled-trial evidence and adds risks in an already inflamed area.
Перекрёстные ссылки безопасности
Clinical Profile
- Category
- ent
- ICD-10
- H60.60, H60.61, H60.62, H60.63
- Safety tier
- high
Evidence Summary
Chronic otitis externa is inflammation of the external ear canal lasting beyond 6 weeks, often with bacterial (Pseudomonas, Staphylococcus) or fungal (Aspergillus, Candida) component. Evidence-based management includes microscopic aural toilet, topical antimicrobial drops (fluoroquinolone-corticosteroid combinations for bacterial, antifungal for fungal), wick placement in canal-stenotic cases, and addressing predisposing factors (water exposure, dermatitis of the canal, cerumen pathology, hearing-aid use). Necrotizing otitis externa in diabetic or immunocompromised patients is a surgical emergency. No published controlled trials of hirudotherapy exist for chronic otitis externa. The external auditory canal is anatomically inaccessible and high-risk; the periauricular region carries facial nerve and arterial risk.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Active bacterial or fungal otitis externa
- Necrotizing (malignant) otitis externa — surgical emergency
- Tympanic membrane perforation
- Ear canal placement
- Cholesteatoma or other middle-ear pathology
- Hearing aid in situ on affected side
Related Conditions
Chronic Rhinosinusitis
Off-label use with one RCT showing symptom and SNOT-22 score improvement at 4 weeks in non-polypoid chronic sinusitis.
Subjective Tinnitus
Investigational use for chronic subjective tinnitus; case-series evidence for THI score improvement. Mechanism speculative.
Ménière's Disease (Adjunctive)
Investigational adjunctive use for Ménière's disease; very limited evidence. Standard management (diet, betahistine, intratympanic therapy) remains primary.
Pulsatile Tinnitus (Vascular-Origin Subtype)
Investigational use for pulsatile vascular-origin tinnitus distinct from subjective tinnitus; case-report evidence only.